Phaseline

Targets › PGR

PGR (Progesterone receptor): drug programs, companies and trials

39 programs from 34 companies in 79 trials: 28 Phase 2, 28 Phase 4, 15 Phase 3, 8 Phase 1; Other, Oncology, Psychiatry; next expected readout Nov 2026.

The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as a transcriptional activator or repressor..; FUNCTION: [Isoform A]: Ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity including repression…. (UniProt, P06401)

Open in Phaseline: the race on PGR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, San FranciscoHormone Replacement Therapy (HRT)
Estrogen and progestin replacement
ESR1, ESR2, PGRPhase 4Adhesive Capsulitis of the ShoulderDec 2026
Changchun GeneScience PharmaceuticalMegestrol Acetate
Progesterone receptor agonist
PGRPhase 4Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia; Non-small Cell Lung Cancer; Neoadjuvant Chemotherapy; Nutrition Disorders …Dec 2026
Oregon Health and Science UniversityUlipristal acetate
Progesterone receptor modulator
PGRPhase 4Contraceptive UsageDec 2026
Insel Gruppe AG, University Hospital BernHormone Replacement Therapy (HRT)
Transdermal estradiol and oral micronized progesterone replacement
ESR1, ESR2, PGRPhase 4InsomniaJan 2027
University of PennsylvaniaEtonogestrel
Progesterone receptor agonist
PGRPhase 4Sickle Cell DiseaseMar 2027
University of UtahLevonorgestrel
Progesterone receptor agonist
PGRPhase 4ContraceptionMar 2027
University of Colorado, DenverLevonorgestrel
Progesterone receptor agonist
PGRPhase 4Oral Hormonal Contraceptive UseMar 2027
Insud PharmaDrospirenone (LF111)
Mineralocorticoid receptor antagonist; Progesterone receptor agonist
NR3C2, PGRPhase 4Change in Bone Mineral Density; ContraceptionDec 2027
University of Colorado, DenverEtonogestrel
Progesterone receptor agonist
PGRPhase 4ContraceptionDec 2027
University Hospital, GhentDesogestrel
Progesterone receptor agonist
PGRPhase 4Ovarian StimulationDec 2027
Lori GawronEtonogestrel
Progesterone receptor agonist
PGRPhase 4Emergency ContraceptionApr 2028
Yale UniversityDesogestrel
Progesterone receptor agonist
PGRPhase 4ContraceptionMay 2028
Peking Union Medical College HospitalFemoston 2/10
Estradiol and dydrogesterone hormone replacement therapy
ESR1, PGRPhase 4Functional Hypothalamic AmenorrheaJun 2028
University of PennsylvaniaDepot medroxyprogesterone acetate (DMPA)
Progestin receptor agonist
PGRPhase 4Sickle Cell Disease (SCD)Jul 2028
Penn State UniversityCombined Oral Contraceptive (COC) / Apri (Reclipsen)
Oral ethinyl estradiol-based contraceptive; estrogen receptor agonist
ESR1, ESR2, PGRPhase 4Other Disorders of Bone Development and GrowthDec 2028
The University of Hong KongDydrogesterone
Progesterone receptor agonist
PGRPhase 3SubfertilityNov 2026
Khyber Medical University PeshawarDanazol
Progesterone receptor agonist; Androgen Receptor agonist
PGR, ARPhase 3Beta-ThalassemiaApr 2027
Leiden University Medical CenterMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 3Female ContraceptionJun 2027
The University of Hong KongLevonorgestrel
Progesterone receptor agonist
PGRPhase 3ContraceptionSep 2027
The University of Hong KongUlipristal Acetate
Progesterone receptor modulator
PGRPhase 3ContraceptionSep 2027
Christiaan VinkersMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 2Treatment-resistant PTSDNov 2026
University of Wisconsin, Madison18F-fluorofuranylnorprogesterone (18F-FFNP)
Progesterone receptor (PR) radioligand
PGRPhase 2Metastatic Cancer; Breast CancerDec 2026
Queensland Centre for Gynaecological CancerLevonorgestrel
Progesterone receptor agonist
PGRPhase 2Complex Endometrial Hyperplasia With AtypiaDec 2026
University of Mississippi Medical Center17-hydroxyprogesterone caproate (17 OHPC)
Progesterone receptor agonist
PGRPhase 2PregnancyJan 2027
Xiaojun ChenLevonorgestrel
Progesterone receptor agonist
PGRPhase 2Atypical Endometrial HyperplasiaFeb 2027
Bedaya HospitalDydrogesterone
Progesterone receptor agonist
PGRPhase 2InfertilityMar 2027
Chelsea and Westminster NHS Foundation TrustMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 2Labor, InducedMar 2027
University of Southern CaliforniaDanazol
Progesterone receptor agonist; Androgen Receptor agonist
PGR, ARPhase 2Cirrhosis, LiverAug 2027
Memorial Sloan Kettering Cancer CenterMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 2Metastatic Breast CancerOct 2027
M.D. Anderson Cancer CenterLevonorgestrel
Progesterone receptor agonist
PGRPhase 2Atypical Endometrial HyperplasiaNov 2027
Fudan UniversityMedroxyprogesterone Acetate
Progesterone receptor agonist
PGRPhase 2Endometrial CancerDec 2027
OHSU Knight Cancer InstituteUlipristal Acetate
Progesterone receptor modulator
PGRPhase 2Mammography ScreeningDec 2027
Yale UniversityEtonogestrel
Progesterone receptor agonist
PGRPhase 2ContraceptionMay 2029
University of Virginiatransdermal 17β-E2 with cyclic progestin
Estrogen receptor agonist with cyclic progestin
ESR1, ESR2, PGRPhase 2Bone StrengthDec 2029
University of ChicagoMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 2Breast Cancer–
Calla Lily Clinical CareProgesterone
Progesterone receptor agonist
PGRPhase 1Luteal Phase Insuffiency; Luteal Support; Smoking; Pregnancy Related …Dec 2026
FHI 360Etonogestrel
Progesterone receptor agonist
PGRPhase 1ContraceptionJun 2027
Montefiore Medical CenterMifepristone
Glucocorticoid receptor antagonist; Progesterone receptor antagonist
NR3C1, PGRPhase 1Cervical PreparationJun 2027
Premier ResearchLevonorgestrel
Progesterone receptor agonist
PGRPhase 1Healthy Women–

Conditions

Contraception (8) Atypical Endometrial Hyperplasia (4) Infertility (4) Endometrial Cancer (3) Bone Strength (3) Luteal Phase Insuffiency (2) Luteal Support (2) Pregnancy Related (2) Turner Syndrome (2) Endometrial Endometrioid Adenocarcinoma (2) Breast Cancer (2) Other Disorders of Bone Development and Growth (2)

Modalities

small molecule (34), mixed (2), protein or peptide (1), other (1)

Companies

The University of Hong Kong (3) Yale University (2) University of Pennsylvania (2) University of Colorado, Denver (2) M.D. Anderson Cancer Center (1) Xiaojun Chen (1) Christiaan Vinkers (1) Calla Lily Clinical Care (1) Montefiore Medical Center (1) Queensland Centre for Gynaecological Cancer (1) Premier Research (1) University of Chicago (1) Leiden University Medical Center (1) Changchun GeneScience Pharmaceutical (1) Lori Gawron (1) Fudan University (1) Khyber Medical University Peshawar (1) Chelsea and Westminster NHS Foundation Trust (1) OHSU Knight Cancer Institute (1) University Hospital, Ghent (1)

Related targets

NR3C1 (6) ESR1 (5) ESR2 (4) AR (2) NR3C2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.